Publications by authors named "Ullrich Graeven"

Claim this Profile
I
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in Wild-Type Metastatic Colorectal Cancer.
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, Beatrice Borelli, Theresa Keller, Ullrich Graeven

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.
Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Ullrich Graeven

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance".
Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Ullrich Graeven

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutations.
Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel, Sebastian Yves Friedrich Michels, Ullrich Graeven

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders.
Markus Wennmann, Jessica Kächele, Arvin von Salomon, Tobias Nonnenmacher, Markus Bujotzek, Ullrich Graeven

Acad Radiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
Alexej Ballhausen, Susanna Swoboda, David Horst, Stefan Fruehauf, Ullrich Graeven

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.
Fabian Bauer, Marina Hajiyianni, Niels Weinhold, Martin Grözinger, Jessica Kächele, Ullrich Graeven

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial.
Lisa B Leypoldt, Linlin Guo, Britta Besemer, Mathias Hänel, Marc-S Raab, Ullrich Graeven

Cardiooncology· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.
Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S Raab, Sandra Sauer, Ullrich Graeven

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Moritz Fürstenau, Sandra Robrecht, Christof Schneider, Eugen Tausch, Adam Giza, Ullrich Graeven

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer.
Ralf-Dieter Hofheinz, Dirk Arnold, Markus Borner, Wolfgang Eisterer, Gunnar Folprecht, Ullrich Graeven

Oncol Res Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.
Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hanel, Marc S Raab, Ullrich Graeven

Future Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Arndt Vogel, Anna Saborowski, Patrick Wenzel, Henning Wege, Gunnar Folprecht, Ullrich Graeven

Lancet Gastroenterol Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8 CD28 regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Katharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, Axel Benner, Uta Bertsch, Ullrich Graeven

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Dominik Paul Modest, Volker Heinemann, Philipp Schütt, Stefan Angermeier, Mike Haberkorn, Ullrich Graeven

J Cancer Res Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Ullrich Graeven

Leukemia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Arndt Stahler, Andreas J Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Ullrich Graeven

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Greta Sommerhäuser, Meinolf Karthaus, Annika Kurreck, Alexej Ballhausen, Johanna W Meyer-Knees, Ullrich Graeven

Int J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans J Salwender, Sonja Zweegman, Ullrich Graeven

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Elias K Mai, Hartmut Goldschmid, Kaya Miah, Uta Bertsch, Britta Besemer, Ullrich Graeven

Lancet Haematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hänel, Marc S Raab, Ullrich Graeven

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics.
Markus Wennmann, Wenlong Ming, Fabian Bauer, Jiri Chmelik, André Klein, Ullrich Graeven

Invest Radiol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Alexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
Arndt Stahler, Beeke Hoppe, Il-Kang Na, Luisa Keilholz, Lothar Müller, Ullrich Graeven

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis